University of California, Santa Cruz

- Safety and immunogenicity of varying dose levels of BNT162b1 and Bnt162b2. The process was followed by testing the vaccine's safety through the proportion of participants exhibiting adverse events, 
- Immunogenicity assessment through a serum neutralization assay before the 7 and 21-day mark after Dose 1, and 21 days and 35 days after dose 2. 


Methods for testing BNT162b2

Zhu, F. C., Li, Y. H., Guan, X. H., Hou, L. H., Wang, W. J., Li, J. X., ... & Jia, S. Y. (2020). Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. doi: 10.1016/S0140-6736(20)31208-3

https://doi.org/10.1016/S0140-6736(20)31208-3

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. 

Learn Before

Related